Clinical

Shaji Kumar, MD, Mayo Clinic, focuses on the selection, outcomes, and real-world impact of BCMA-targeted bispecific antibodies for multiple myeloma. He emphasizes the factors influencing choice of linvoseltamab, teclistamab, and elranatamab; addresses the impressive results from the LINKER-MM1 trial, which served as the basis for linvoseltamab’s FDA approval; and speaks to linvoseltamab’s new inclusion as a preferred agent in NCCN Guidelines.

Shaji Kumar, MD, Mayo Clinic, discusses the July approval of linvoseltamab, a new bispecific antibody for relapsed myeloma, and how it expands treatment options for patients. He also emphasizes the unique characteristics of linvoseltamab, such as its intravenous administration and flexible dosing schedule.

Although children living with myopia taking atropine did experience an increased incidence of cataracts, glaucoma, or maculopathy, it is unclear if this risk was confounded by myopia severity.

Refat Rasul Srejon, MPH, found that Affordable Care Act (ACA) dependent coverage had mixed effects on young adults’ substance-related emergency department (ED) visits.

The 2024-2025 influenza season saw record-high hospitalization rates, prompting the CDC to emphasize the importance of vaccination and early antiviral treatment.

This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.

Ovarian and uterine cancers linked to high body mass index (BMI) have steadily increased among women of reproductive age, with the greatest burden observed in low- and middle-sociodemographic index regions.

From respiratory conditions to rare diseases and beyond, here are 5 groundbreaking FDA approvals from last month.

Panelists discuss how health care providers need coordinated multidisciplinary care teams, visual resources like databases for eczema in skin of color, peer-to-peer educational sessions, and case-based learning to better recognize and manage atopic dermatitis (AD) across diverse skin tones.

Panelists discuss how treatment access challenges require provider advocacy through peer-to-peer reviews and patient assistance programs, whereas cost-effectiveness evaluation focuses on time to specialist care, therapy duration, and quality-of-life outcomes.

Patients with bronchiectasis who are highly symptomatic face an increased risk of future exacerbations, suggesting symptoms should guide prevention strategies.

Bone density was found to be lower in those diagnosed with HIV vs those who were HIV-negative.

Adults with food insecurity report higher rates of long COVID and lower recovery, with Supplemental Nutrition Assistance Program (SNAP) participation and employment status affecting these associations.

The use of cemiplimab with chemotherapy showed durable improvements in survival outcomes for non-small cell lung cancer (NSCLC) after 5 years.

AD-related outcomes were compared in patients treated with JAK1 inhibitors and IL-13 antibodies, with short-term efficacy biomarkers considered for treatment outcomes.

Subcutaneous amivantamab plus chemotherapy offers an equally effective treatment for EGFR exon 20 insertion non–small cell lung cancer (NSCLC), mirroring PAPILLON results of the intravenous formulation, explained Sun Lim Min, MD, PhD.

This article reviews the safety, efficacy, and regulatory concerns related to compounded semaglutide, with a focus on how health care providers can offer guidance and education to patients.

Extended hospital stays among Medicare Advantage beneficiaries translated to an estimated 1.8 million additional hospital bed days in 2022.

While body mass index (BMI) accurately identified excess adiposity in nearly all children and adolescents with obesity, it failed to detect many of those without obesity who still had excess body fat.

More frequent routine primary care visits for certain higher-risk commercially insured adults are associated with lower net population-level health care costs.

Discontinuing dupilumab for atopic dermatitis (AD) may increase relapse risk, which requires ongoing management and tailored treatment strategies to manage that risk.

Panelists discuss how biologic therapy selection depends on disease burden rather than just body surface area (BSA), with monitoring requiring objective measures, patient-reported outcomes, and specialized photography documentation for patients with darker skin tones.

Panelists discuss how patients with darker skin tones often experience delayed diagnosis due to misidentification as fungal infections or other conditions, emphasizing the importance of shared decision-making and patient education about the immune-mediated nature of the disease.

Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).

BeOne Medicines reveals promising results for sonrotoclax, a next-gen BCL2 inhibitor, in treating relapsed mantle cell lymphoma, addressing critical patient needs.

New abstracts from the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025 found that ACC017 showed promise in its use as an antiretroviral therapy.

A new study evaluated real-world data on the efficacy of GLP-1s in patients with obesity and heart failure with preserved ejection fraction (HFpEF), confirming findings from prior research.

Long-term follow-up data on the use of BCMA-directed RNA chimeric antigen receptor T-cell therapy (CAR T) for refractory generalized myasthenia gravis show patient outcomes at 2, 3, 6, 9, and 12 months.

Patients had better linkage to care for HIV and HIV was more frequently diagnosed when it was tested alongside other sexually transmitted infections (STIs), such as chlamydia and gonorrhea.

Ovarian cancer deaths remain uneven across age, geography, and racial and ethnic groups, highlighting the need for targeted interventions.